You are here:
| Reference : Zoledronate inhibits alpha v beta 3 and alpha v beta 5 integrin cell surface expression ... |
| Scientific journals : Article | |||
| Life sciences : Biochemistry, biophysics & molecular biology Human health sciences : Oncology Human health sciences : Pharmacy, pharmacology & toxicology | |||
| http://hdl.handle.net/2268/24067 | |||
| Zoledronate inhibits alpha v beta 3 and alpha v beta 5 integrin cell surface expression in endothelial cells | |
| English | |
Bellahcene, Akeila  [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases >] | |
| Chaplet, Michael [> > > >] | |
| Bonjean, K. [> > > >] | |
| Castronovo, Vincenzo [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire >] | |
| 2007 | |
| Endothelium : Journal of Endothelial Cell Research | |
| Taylor & Francis Inc | |
| 14 | |
| 2 | |
| 123-130 | |
| International | |
| 1062-3329 | |
| Philadelphia | |
| [en] angiogenesis ; GTPases ; integrins ; zoledronate | |
| [en] Zoledronate exhibits antiangiogenic properties in vitro and in vivo. Integrins alpha v beta 3 and alpha v beta 5 are involved in angiogenesis. Because zoledronate inhibits endothelial cell adhesion, the authors explored the hypothesis that it could alter these integrins recruitment to focal adhesion sites. Human umbilical vein endothelial cells ( HUVECs) were treated with zoledronate or with mevalonate pathway intermediates geranylgeraniol ( GGOH) and farnesol (FOH). Zoledronate generated a significant decrease in alpha v beta 3 and alpha v beta 5 expression at HUVEC cell surface using flow cytometry and immunofluorescence. This inhibition was reversed by GGOH but not by FOH. Cells cotreated with zoledronate and GGOH were able to attach to vitronectin through alpha v beta 3 and alpha v beta 5, as confirmed by the use of specific function-blocking antibodies. The authors showed that zoledronate alters endothelial cell integrin-mediated adhesion. This effect is likely to contribute to the previously demonstrated antiangiogenic effect of zoledronate. Whether this mechanism of action also applies to metastatic tumor cells is under investigation. | |
| Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS ; Inter-University Attraction Pole (IAP-P5/31) ; Fonds Spéciaux de l'Université de Liège ; European Commission (METABRE) | |
| http://hdl.handle.net/2268/24067 | |
| 10.1080/10623320701347187 |
| File(s) associated to this reference | ||||||||||||||
|
Fulltext file(s):
| ||||||||||||||
All documents in ORBi are protected by a user license.
